17 completed, 2 recruiting, 1 not yet recruiting, 1 unknown. 11 Phase 1, 5 Phase 3, 4 Phase 2, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 10, Recruiting 1 |
| Phase 3 | 5 | Completed 5 |
| Phase 2 | 4 | Recruiting 2, Completed 1, Unknown 1 |
| Early Phase 1 | 1 | Not yet recruiting 1 |
| Not applicable | 1 | Completed 1 |
Follow eliglustat: new trials by email Literature Review of eliglustat trials Research Report on eliglustat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC. Regorafenib+Immune checkpoint inhibitor, Eliglustat+Immune checkpoint inhibitor, Eliglustat+Immune checkpoint inhibitor +Regorafenib - Colorectal Cancer | Phase 2 | Recruiting | Chinese PLA General Hospital | 120 | 2026-03-01 | 2026-02-11 |
| GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma Eliglustat, CD30 target immunotherapy - Lymphoma | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 40 | 2025-12-26 | 2026-01-02 |
| GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma. Eliglustat - Neuroblastoma | Early Phase 1 | Not yet recruiting | Chinese PLA General Hospital | 10 | 2025-08-01 | 2025-07-29 |
| Efficacy and Safety of Eliglustat in Chinese Pediatric Patients With Gaucher Disease Type 1 and Type 3 Eliglustat Tartrate Capsules - Gaucher Disease | Phase 2 | Unknown | Peking Union Medical College Hospital | 5 | 2024-08-01 | 2024-07-26 |
| GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor Eliglustat, Immune checkpoint inhibitor - Solid Tumor, Hematologic Malignancy | Phase 1 | Completed | Chinese PLA General Hospital | 31 | 2021-07-01 | 2023-12-19 |
| Eliglustat on Gaucher Disease Type IIIB Eliglustat - Gaucher Disease, Type III | Not applicable | Completed | National Taiwan University Hospital | 4 | 2018-04-23 | 2022-09-15 |
| Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3 Eliglustat GZ385660, Imiglucerase GZ437843 - Gaucher's Disease Type I, Gaucher's Disease Type III | Phase 3 | Completed | Sanofi | 57 | 2018-04-11 | 2026-06-16 |
| A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor Metabolizers Eliglustat - Gaucher's Disease | Phase 1 | Completed | Sanofi | 18 | 2018-01-01 | 2024-01-10 |
| Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 Studies Eliglustat, GZ385660 - Gaucher Disease | Phase 3 | Completed | Genzyme, a Sanofi Company | 31 | 2015-10-27 | 2022-07-15 |
| A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate eliglustat - Gaucher Disease | Phase 1 | Completed | Genzyme, a Sanofi Company | 24 | 2015-09-01 | 2017-02-10 |
| A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate eliglustat - Gaucher Disease | Phase 1 | Completed | Sanofi | 32 | 2015-09-01 | 2017-03-08 |
| Taste Evaluation of Different Liquid Formulations With Eliglustat eliglustat - Gaucher Disease | Phase 1 | Completed | Genzyme, a Sanofi Company | 8 | 2015-04-01 | 2015-05-27 |
| A Study to Evaluate Pharmacokinetic Parameters and Safety of Eliglustat Absorption Through the Mouth Eliglustat - Gaucher's Disease | Phase 1 | Completed | Sanofi | 6 | 2014-08-25 | 2024-01-05 |
| Study to Evaluate the Effect of Eliglustat on the Pharmacokinetics, Safety and Tolerability of Metoprolol in Healthy Adults Eliglustat, Metoprolol - Healthy | Phase 1 | Completed | Genzyme, a Sanofi Company | 14 | 2012-05-01 | 2015-03-23 |
| A Phase I Study of the Pharmacokinetic Variability and Relative Bioavailability of the Phase 3 and Common Blend Formulations of Eliglustat in Healthy Adult Subjects Eliglustat, common blend proposed commercial formulation, Eliglustat, Phase 3 capsule formulation - Healthy Volunteer | Phase 1 | Completed | Genzyme, a Sanofi Company | 22 | 2011-10-01 | 2015-03-23 |
| A Phase 1 Study Evaluating Eliglustat's Effects on Pharmacokinetics, Safety & Tolerability of Digoxin in Healthy Adults eliglustat; digoxin, digoxin - Healthy Volunteer | Phase 1 | Completed | Genzyme, a Sanofi Company | 28 | 2011-08-01 | 2015-03-23 |
| A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE) Eliglustat tartrate - Gaucher Disease | Phase 3 | Completed | Genzyme, a Sanofi Company | 170 | 2010-06-01 | 2017-02-06 |
| A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE) Eliglustat tartrate, Placebo - Gaucher Disease, Type 1 | Phase 3 | Completed | Genzyme, a Sanofi Company | 40 | 2009-11-01 | 2017-03-03 |
| A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE) Eliglustat tartrate, Imiglucerase - Gaucher Disease, Type 1 | Phase 3 | Completed | Genzyme, a Sanofi Company | 160 | 2009-09-01 | 2016-11-25 |
| A Study to Evaluate Absolute Bioavailability, Absorption, Metabolism, and Excretion of Genz-112638 in Healthy Male Participants Genz-112638, [14C]-Genz-112638 - Gaucher's Disease Type I | Phase 1 | Completed | Sanofi | 10 | 2009-06-03 | 2023-11-22 |
Showing 20 of 21. Sign in to see all of them.
Gaucher Disease (14) · Colorectal Neoplasms (1) · Hematologic Neoplasms (1) · Lymphoma (1) · Neuroblastoma (1)
Genzyme, a Sanofi Company (10) · Sanofi (5) · Chinese PLA General Hospital (4) · National Taiwan University Hospital (1) · Peking Union Medical College Hospital (1)
United States (12) · China (6) · Russia (6) · Canada (5) · Argentina (3) · France (3) · Italy (3) · United Kingdom (3) · Australia (2) · Brazil (2) · India (2) · Israel (2) · Japan (2) · Mexico (2) · Serbia (2)
Bing Han (1) · Ni-Chung Lee, M.D., Ph.D (1) · Weidong Han (1) · Weidong Han, Ph.D (1) · Weidong Han, PhD (1)
PMID 36739645, PMID 20439622, PMID 20713962, PMID 24816856, PMID 24835462, PMID 25688781, PMID 25819691, PMID 28167660, PMID 29358012, PMID 34161616, PMID 39774103
2008 (2), 2005 (1), 2009 (1), 2016 (1)